Synlab

Synlab

Medical diagnostic laboratory services provider

About Synlab

Simplify's Rating
Why Synlab is rated
C+
Rated B on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Company Size

5,001-10,000

Company Stage

Acquired

Total Funding

$1.7B

Headquarters

Munich, Germany

Founded

1998

Overview

SYNLAB provides a full range of medical laboratory services for practicing doctors, clinics, and patients. Its diagnostic tests cover human medicine and are processed through a wide network of labs across 36 countries and four continents, making it a leading partner for laboratory diagnostics in Europe. Tests are performed in certified laboratories using standardized procedures to deliver fast, reliable, high-quality results that doctors use to diagnose and monitor conditions. SYNLAB differentiates itself through its large European footprint, integrated laboratory network, and scale, which enable consistent, timely diagnostics across many sites. The company’s goal is to support better patient care by expanding access to accurate and efficient laboratory testing.

Simplify Jobs

Simplify's Take

What believers are saying

  • Region Stockholm awarded 5-year contract starting April 2027 for diagnostics.
  • Labcorp acquired minority stake in 2024, enabling specialty test collaborations.
  • Cinven acquired Elliott's 10% stake in October 2024, consolidating control.

What critics are saying

  • Eurofins acquired Synlab Spain, eroding Iberian revenue immediately.
  • Medicover acquires Romanian labs, stripping Eastern European assets now.
  • Synnovis ransomware hack in June 2024 damaged UK trust and capacity.

What makes Synlab unique

  • SYNLAB leads European medical diagnostics with 500 labs across 36 countries.
  • Offers 5,000+ tests including clinical chemistry, microbiology, and pathology.
  • Operates 1,800+ blood collection points for accessible patient services.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.7B

Above

Industry Average

Funded Over

2 Rounds

Buyout funding comparison data is currently unavailable. We're working to provide this information soon!
Buyout Funding Comparison
Coming Soon

Benefits

Wellness Program

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

1%
PharmiWeb.com
Mar 25th, 2025
Cinven Sells SYNLAB Stake to Labcorp

Cinven has completed the sale of an indirect minority stake in SYNLAB to Labcorp, a global leader in laboratory services. SYNLAB, a major player in medical diagnostics in Europe, achieved revenues of €2.62 billion in 2024. The companies plan to explore opportunities for Labcorp's specialty tests in Europe and potential collaborations. Labcorp, with nearly 70,000 employees, supported over 75% of new FDA-approved drugs in 2024.

Iberian Lawyer
Nov 5th, 2024
GA_P advises Synlab Group in the sale of Synlab España to Eurofins - Iberian Lawyer

Gómez-Acebo & Pombo has advised the Synlab Group, a leader in medical diagnostic services and specialized tests in Europe, in the sale of Synlab Spain to Eurofins Scientific (EUFI.PA).

PEI Group
Oct 30th, 2024
Cinven agrees to sell minority stake in Synlab | PE Hub

Synlab is a medical diagnostic services and specialty testing provider.

PharmiWeb.com
Oct 30th, 2024
Cinven To Acquire Elliott’S Stake In Synlab Ag, Squeeze-Out To Follow

EQS-News: SYNLAB AG / Key word(s): Miscellaneous/Squeeze OutCinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow30.10.2024 / 07:32 CET/CESTThe issuer is solely responsible for the content of this announcement.Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreement, Cinven will acquire Elliott’s current direct minority stake of approximately 10% in SYNLAB. Elliott will become an indirect minority shareholder in SYNLAB, alongside existing shareholders Cinven, Labcorp (subject to regulatory approval), and Qatar Holding LLC. The transaction is subject to regulatory approvals and is expected to close in early 2025. The acquiring entity of Elliott’s shareholding will be Ephios Bidco GmbH (“Ephios Bidco”), an entity controlled by funds managed and/or advised by Cinven and the majority shareholder of SYNLAB AG. Ephios Bidco currently holds approximately 86% of the SYNLAB share capital

SYNLAB
Oct 28th, 2024
SYNLAB agrees to sell its Spanish business to Eurofins

SYNLAB agrees to sell its Spanish business to Eurofins.

Recently Posted Jobs

Sign up to get curated job recommendations

Synlab is Hiring for 9 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →